HKD 1.28
(4.92%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 108.85 Million USD | -22.04% |
2022 | 139.62 Million USD | 134.87% |
2021 | 59.44 Million USD | 114.38% |
2020 | 27.73 Million USD | -87.56% |
2019 | 222.94 Million USD | 31.63% |
2018 | 169.37 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 96.89 Million USD | 0.0% |
2024 Q1 | 96.89 Million USD | -10.98% |
2023 Q2 | 123.15 Million USD | 0.0% |
2023 Q1 | 123.15 Million USD | -11.8% |
2023 Q4 | 108.85 Million USD | 0.0% |
2023 FY | 108.85 Million USD | -22.04% |
2023 Q3 | 108.85 Million USD | -11.61% |
2022 Q2 | 111.5 Million USD | 0.0% |
2022 FY | 139.62 Million USD | 134.87% |
2022 Q4 | 139.62 Million USD | 0.0% |
2022 Q3 | 139.62 Million USD | 25.21% |
2022 Q1 | 111.5 Million USD | 87.58% |
2021 Q4 | 59.44 Million USD | 0.0% |
2021 Q1 | 23.14 Million USD | -16.53% |
2021 Q2 | 23.14 Million USD | 0.0% |
2021 Q3 | 59.44 Million USD | 156.82% |
2021 FY | 59.44 Million USD | 114.38% |
2020 FY | 27.73 Million USD | -87.56% |
2020 Q4 | 27.73 Million USD | 0.0% |
2020 Q3 | 27.73 Million USD | -91.45% |
2020 Q2 | 324.25 Million USD | 0.0% |
2020 Q1 | 324.25 Million USD | 45.44% |
2019 Q1 | - USD | 0.0% |
2019 Q3 | 222.94 Million USD | 0.0% |
2019 Q4 | 222.94 Million USD | 0.0% |
2019 FY | 222.94 Million USD | 31.63% |
2018 FY | 169.37 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | 28.771% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 98.458% |